Condition
Unilateral Retinoblastoma
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05504291Phase 2Recruiting
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
NCT03932786Recruiting
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT03475121Phase 3CompletedPrimary
Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma
NCT02097134Phase 1CompletedPrimary
Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Showing all 4 trials